Search tips
Search criteria 


Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS ONE. 2007; 2(9): e828.
Published online 2007 September 5. doi:  10.1371/journal.pone.0000828
PMCID: PMC1952174

Regulation of Retention of FosB Intron 4 by PTB

Juan Valcarcel, Academic Editor


One effect of stressors such as chronic drug administration is that sequence within the terminal exon of the transcription factor FosB is recognized as intronic and removed by alternative splicing. This results in an open-reading-frame shift that produces a translation stop codon and ultimately a truncated protein, termed ΔFosB. In vitro splicing assays with control and mutated transcripts generated from a fosB mini-gene construct indicated a CU-rich sequence at the 3′ end of intron 4 (I4) plays an important role in regulating fosB pre-mRNA splicing due to its binding of polypyrimidine tract binding protein (PTB). PTB binding to this sequence is dependent upon phosphorylation by protein kinase A and is blocked if the CU-rich sequence is mutated to a U-rich region. When this mutated fosB minigene is expressed in HeLa cells, the splicing efficiency of its product is increased compared to wild type. Moreover, transient transfection of PTB-1 in HeLa cells decreased the splicing efficiency of a wild type fosB minigene transcript. Depletion of PTB from nuclear extracts facilitated U2AF65 binding to wild type sequence in vitro, suggesting these proteins function in a dynamic equilibrium to modulate fosB pre-mRNA alternative splicing. These results demonstrate for the first time that phosphorylated PTB promotes intron retention and thereby silences the splicing of fosB I4.


Fos and jun are immediate early genes that are expressed rapidly and transiently in the nucleus accumbens (NAc) and other regions of the brain in response to a variety of stressors such as substantia nigra lesions, drug withdrawal and electrical stimulation [1], [2], [3], [4]. These genes encode proteins that are members of the activator protein 1 (AP-1) family of transcription factors. The transcription factors form either heterodimers or homodimers and activate expression by binding to AP-1 sites upstream of particular genes, such as those encoding growth factors and neurotransmitters [1]. Products of the fos gene family include cFos, Fos-related antigens (referred to as Fra1 and Fra2) and FosB.

While the 45 kDa FosB protein is only transiently expressed in the brain, ΔFosB, a 33–37 kDa splice variant of FosB, accumulates in a region-specific manner as a common response to chronic stimuli [4], [5], [6], [7], [8]. ΔfosB mRNA is produced by removal of intron 4 (I4) within the terminal exon of the fosB pre-mRNA. This regulated splicing event results in translation termination and the production of a truncated protein. Three factors have been identified that contribute to ΔFosB protein accumulation. These include the repeated activation of the fosB gene and induction of ΔfosB mRNA [9]; the absence of a C-terminal destabilizing domain in the case of ΔFosB protein, but not for the other members of the Fos family [10]; and the phosphorylation of an N-terminal serine residue on ΔFosB, which is important in inhibiting proteosomal degradation [11].

Sequencing of the human genome resulted in the surprising finding that more than 42% of the genes produce pre-mRNAs that are alternatively spliced [12], [13], [14], [15]. Many of the regulated splicing events occur in neurons and the molecular basis of the neural specificity is only beginning to be understood [16], [17]. Coding sequences of eukaryotic genes (exons) are interspersed by non-coding sequences (introns) that can be removed from the pre-mRNA by splicing in either a constitutive or a regulated manner. The accurate elimination of these non-coding regions requires a conserved 5′ splice site, a branch point sequence, and a polypyrimidine tract that precedes the 3′ splice site. Interestingly, recent research has indicated that elements critical for the regulation of pre-mRNA splicing may also be found both proximal and distal to the traditional splice sites. These sequences are termed enhancer or silencer elements and can be functional within both introns or exons [18]. Whether the sequence acts as an activator or inhibitor of splicing appears to be context-dependent [19]. Two well-studied examples of exon skipping are those of c-src and GABAA receptor γ2 subunit pre-mRNAs, which contain the pyrimidine-rich sequences CUCUCU, UUCUCU, UUCCUU and CUUCUUC [20], [21], [22]. PTB binds these sequences and by doing so functions to silence splicing. The sequence CUCCUCUUCC within transcript generated from the human calcitonin/calcitonin gene-related peptide (CT/CGRP) gene also binds PTB but in this case it enhances inclusion of the adjacent exon 4 into the mRNA [23]. A CU-rich sequence similar to these examples is found proximal to the 3′ end of fosB I4. More recently it was reported that PTB can also counteract the splicing inhibitory activity of SRp30c [24].

Along with identifying target genes that are regulated by the Fos family of transcription factors, recent work has focused on deciphering the regulation of FosB isoform expression. In this study we have used an in vitro splicing system to identify PTB as a factor that binds the 3′ end of fosB I4 in a PKA phosphorylation-dependent manner. A CU-rich sequence is required for PTB binding and regulates I4 retention in vitro as well as in vivo. We also show that U2AF65, a factor important in the assembly of the splicing machinery, can bind to the 3′ end of fosB I4. Interestingly, reducing the amount of PTB bound to the 3′ end of fosB I4, by either PTB depletion or mutation of the CU-rich PTB binding element, results in increased binding of U2AF65 to fosB I4. These findings support a model in which a competition between PTB and U2AF65 regulates fosB I4 retention.


The two splice variants of fosB are products of intron retention (fosB) and intron excision (ΔfosB). A sequence of 140 nt proximal to the 3′ end of the fosB pre-mRNA (Fig. 1A) is removed by splicing to produce ΔfosB mRNA. Visual inspection of the 5′ and 3′ splice sites of the regulated fosB intron, I4, and the upstream and downstream exons 4 and 5 (E4 and E5), revealed that it has been very well conserved between humans, rats and mice (Fig. 1B). However, comparison of the I4 splice site of mammals with that of fish indicated that regulated fosB pre-mRNA splicing has not been evolutionarily conserved among all vertebrates (Fig. 1B). The 3′ splice site of the mammalian fosB I4 is suboptimal when compared to the splice site consensus sequence. One notable change from the consensus sequence is that the first nucleotide of the downstream exon is a U, which deviates from the G present in the consensus sequence. This deviation produces a sequence similar to the consensus 5′ splice site sequence, thereby potentially creating a pseudo 5′ splice site adjacent to the 3′ splice site (Fig. 1B, underlined sequence). The weakness of this splice site is likely to be an important factor in why I4 is usually retained when fosB is expressed.

Figure 1
Comparison of fosB I4 sequence among vertebrates.

Characterization of I4 Binding Proteins

With regards to splicing regulation, the binding of cis-acting RNA elements becomes very important in dictating whether the spliceosome is recruited to weak splice sites within the pre-mRNA. In order to identify factors that are necessary for the regulated splicing of I4, we created a fosB minigene containing exon 4, intron 4 and exon 5 (E4, I4 and E5). The fosB sequence was cloned downstream to a T7 polymerase promoter to facilitate production of transcripts. Previous studies showed that serum stimulated HeLa cells produce both FosB and ΔFosB and, therefore, the factors essential for the recognition of I4 are present in these cells [25]. In order to determine which proteins bound to I4 of fosB, radioactively-labeled transcripts were prepared from the 5′, middle and 3′ end of the intron (refer to Fig 1A) and used as substrates in UV cross-linking assays (Fig. 2A). The results from these studies indicated that different subsets of proteins bound to each portion of the intron and that an abundant 59 kDa protein bound the 3′ end of the intron (Fig. 2A, lanes 1–6). Visual inspection of the sequence at the 3′ end of the intron indicated that a putative PTB binding site is present within the polypyrimidine tract at the end of the sequence (Fig. 1A, underlined sequence). PTB is approximately 59 kDa and it binds CUCUCUU sequences in other regulated transcripts [20], [21], [22]. A cross-linking immunoprecipitation assay using an antibody specific for PTB or a control antibody showed that PTB bound to the 3′ end of fosB I4 (Fig. 2B, lane 3).

Figure 2
PTB binds to the 3′ end of fosB I4.

PTB Regulates Retention of FosB I4

To characterize the role of PTB in the regulation of FosB pre-mRNA splicing, HeLa cells were co-transiently transfected with a plasmid expressing fosB (ISS/WT) and either a control plasmid (bluescript, pBS) or a construct containing cDNA corresponding to PTB 1. Forty-eight hours post-transfection RNA was isolated from the transfected cells and cDNA prepared. Ectopically expressed fosB sequence was amplified by semi-quantitative PCR using primers complementary to sequence within the vector and exon 5 (Fig 3). Expression of PTB 1 by transient transfection resulted in a significant decrease in fosB I4 splicing. This effect was gradually diminished when decreasing amounts of the PTB 1 plasmid were used in the transfection assay.

Figure 3
In vivo splicing of fosB I4 is regulated by PTB.

Analysis of the PTB Binding Site Within the 3′ End of I4

We next sought to repress the expression of PTB within HeLa cells by siRNA technology and determine what effect this would have on the level of splicing of transcripts generated from the fosB minigene construct. Although we were able to reduce both the mRNA and protein levels of PTB (data not shown), we were not able to achieve enough of a reduction to have a significant effect on the splicing of transcripts generated from the fosB minigene construct. Therefore, we undertook an alternative approach. The fosB minigene was modified by site-directed mutagenesis in such a manner that the PTB binding site within the 3′ end of I4 was eliminated, but the pyrimidine-rich nature of the sequence was maintained (Fig. 4A, ISS/T6). This construct was then used for both in vitro splicing assays and transient transfection in HeLa cells to further explore the functional effects of the mutation. This approach eliminates the non-target artifacts obtained by siRNA technology. In addition, the global decrease of PTB within cells induced by siRNAs would effect numerous other pre-mRNA reactions and biological processes that are regulated by PTB besides fosB splicing. By contrast, the dominant negative mutation exclusively disrupts the interaction of PTB with fosB I4. Thus, using this approach we are able to obtain a more focused analysis of the role of PTB in the regulated splicing of fosB pre-mRNA.

Figure 4
The CT-rich sequence of fosB I4 is required for PTB binding and fosB transcript splicing in vitro and in vivo.

Transcripts corresponding to the 3′ end of fosB I4 were generated from wild type and mutant constructs and used in cross-linking immunoprecipitation assays. The mutations within the CU-rich region disrupted PTB cross-linking to the 3′ sequence of fosB I4 (Fig. 4A, compare lanes 1–4 to lanes 5–8). The results from these studies indicated that one element critical for PTB binding was within the CUCUU sequence.

In order to assess whether PTB regulates processing of the fosB pre-mRNA, in vitro splicing assays were performed with transcripts prepared from constructs containing the ISS/wild type sequence or the ISS/T6 mutation (Fig. 4B). The sizes of the intron retained (IR), intron spliced (IS) and E4 RNAs are 444, 303 and 207 nucleotides (nt), respectively. The products of the splicing assays were confirmed by eluting RNA from the gel and amplifying by PCR using intron- and exon-specific primers (Table 1). Amplification of IR and IS RNAs produced PCR products of 241 and 181 nt, respectively, while the size of the amplified lariat structure was 150 nt (Fig. 4C). The results from the splicing assays showed that when compared to ISS/wild type, the amount of IS increased and IR decreased when the splicing reaction contained ISS/T6 as the source of the transcript (Fig. 4B, lanes 2 and 4). These findings provide support for a regulatory role of PTB in the alternative splicing of the fos B pre-mRNA.

Table 1
Oligodeoxynucleotides used in subcloning, PCR, UV cross-linking and mutagenesis studies.

ISS/WT or ISS/T6 reporter fosB minigenes were transiently expressed in HeLa cells to further explore the effects on splicing due to the loss of binding of PTB to the 3′ end of I4. Forty-eight hours post-transfection RNA was isolated from the transfected cells, cDNA prepared and then analyzed by semi-quantitative PCR with a single set of primers that detect both I4 retained and spliced transcripts generated from the control and mutagenized fosB minigene constructs. The site directed mutagenesis of the PTB binding site in the 3′ end of I4 resulted in a significant enhancement of splicing of the fosB minigene transcript (Fig 4D). These results together with those of the PTB binding assays and in vitro and in vivo splicing assays established a strong correlation between PTB binding to the 3′ end of fosB I4 and intron retention. The decrease in the ratio of IS to IR when excess PTB is present within HeLa cells transfected with ISS/T6 suggests that other PTB binding sites may be able to influence splicing of the fosB when the ISS of I4 is mutated. Notably, while the presence of excess PTB for the control condition (ISS/WT) results in an ~3-fold reduction in the ratio of IS to IR (Fig 3), this reduction for the experimental condition (ISS/T6) is less than 2-fold (Fig 4D). This strongly supports the important role of PTB binding to sequence within the 3′ end of I4 for regulated splicing of fosB pre-mRNA.

Requirement of PTB Phosphorylation for I4 Interaction

Earlier research has shown that phosphorylation can modulate the intracellular transport of PTB, offering a potential means for regulation of its activity in the nucleus [26]. In order to determine whether dephosphorylation of PTB is important for regulating its binding to fosB I4, His-tagged PTB 1 was expressed by transient transfection and isolated from HeLa cells. The isolated protein was cross-linked to the 3′ wild type transcript before or after phosphatase treatment. PTB bound the fosB I4 transcript (Fig. 5, lane 1), and binding was abolished only when phosphatase treatment preceded the cross-linking step (Fig. 5, compare lanes 2 and 3). Previously PTB was shown to be phosphorylated by PKA [26]. In our studies, supplementing the reaction with the catalytic subunit of PKA and ATP, following the phosphatase treatment, was sufficient to rescue PTB binding to the 3′ transcript (Fig. 5B, lane 4). Cross-linking of PTB to this transcript prevents any further disruption of the protein-RNA interaction (Fig. 5, lane 5). The results from these studies suggested that it is not merely the presence of a PTB binding site within the 3′ end of I4 that influences the splicing of fosB pre-mRNA, but rather that this functional interaction is tightly regulated by the PKA-dependent phosphorylation state of PTB.

Figure 5
Alkaline phosphatase treatment results in the lack of PTB binding to the 3′ end of fosB I4.

Depletion of PTB Results in Enhanced Binding of U2AF65 to I4

The CU-rich element characterized in this study is located within the pyrimidine-rich tract upstream of the fosB I4 3′ splice site, a region to which the constitutive splicing factor U2AF65 binds. One explanation for how PTB silences I4 splicing is that it competes with U2AF65 for binding to the intron. To test this hypothesis, we examined whether PTB depletion of the HeLa nuclear extracts would enhance binding of U2AF65 to the 3′ wild type sequence of I4. PTB was depleted from the nuclear extracts by incubation with biotin-labeled PTB substrate and streptavidin precipitation as previously described [22]. 32P-labeled RNA substrate corresponding to the 3′ region of I4 were incubated in the presence of either control HeLa nuclear extract (Fig. 6A, lanes 1 and 3) or PTB-depleted HeLa nuclear extract (Fig. 6A, lanes 2 and 4). Following UV cross-linking, the nuclear extracts were immunoprecipitated with either an α-PTB antibody (Fig. 6A, lanes 1 and 2) or an α-U2AF65 antibody (Fig. 6A, lanes 3 and 4). Samples were resolved by SDS-PAGE and visualized by autoradiography. U2AF65 interaction with the 3′ end of I4 was enhanced when the HeLa nuclear extract was first depleted of PTB (Fig. 6A, lanes 3 and 4). Additionally, we analyzed the binding of U2AF65 to transcripts which contain the mutagenized PTB binding site within the 3′ end of I4. 32P-labeled transcripts corresponding to the 3′ end of fosB I4 generated from ISS/WT (Fig 6B, lanes 1 and 3) and ISS/T6 (Fig 6B, lanes 2 and 4) were incubated in the presence of HeLa nuclear extract before UV cross-linking. Samples were then immunoprecipitated with either an α-PTB antibody (Fig 6B, lanes 1 and 2) or an α-U2AF65 antibody (Fig 6B, lanes 3 and 4), resolved by SDS-PAGE, and visualized by autoradiography. The decreased level of PTB interaction with the 3′ end of I4 due to the T6 mutation resulted in a corresponding increase of U2AF65 binding to the mutagenized transcript (Figure 6B, lane 2 and 4). In summary, it appears that PTB and U2AF65 may compete for binding to the 3′ end of fosB I4 thus providing an additional level of regulation for the splicing of the fosB pre-mRNA.

Figure 6
PTB and U2AF65 bind to the 3′ end of fosB I4.


The brain's ability to adapt in due course to repeated insults can be characterized by the longevity of the response, even after the perturbation has halted. Some examples of such adaptations include learning and memory as well as drug addiction and severe stress [1], [3]. Understanding the molecular basis underlying the stability of these responses has received much attention from the scientific community. The multifaceted process of gene expression is critical to the brain's adaptive response. Therein, considerable research has been focused on the function and regulation of transcription factors including FosB [8], [27], [28], [29].

FosB has been of particular interest since several isoforms, generated by alternative splicing, are differentially expressed in the brain. To date, the expression of ΔFosB is one of the longest-lasting molecular changes produced by chronic drug administration observed in the brain. It is therefore thought to mediate some of the neural and behavioral changes that occur with drug addiction [1], [30]. ΔFosB protein accumulates in the NAc and dorsal striatum of animals chronically treated with cocaine [6]. The truncated protein is produced when a usually retained intron, I4, is deleted from the fosB pre-mRNA by alternative splicing. The removal of I4 results in a shift in the open reading frame and produces a translation stop codon [31]. In this study we show for the first time that the binding of PTB to a CU-rich region within the 3′ end of fosB I4 prevents the splicing of I4 and hence the downstream production of mRNA encoding ΔFosB.

PTB Regulates Intron Retention

In many examples of splicing regulation, the role of PTB is to enhance exon skipping by antagonizing exon definition [22]. Exon definition is the standard mode of recognition of splice sites in vertebrates where genes are composed of relatively short exons interspersed between long introns. In contrast, yeast and other organisms with short introns the usual mode of splice site recognition is by intron definition. The role of PTB in fosB splicing is somewhat unusual in that it is similar to intron definition since the I4 is only 140 nt long. Our data suggest that when PTB binds to fosB pre-mRNA, I4 is retained. Mutating the CU-rich sequence to a U-rich sequence inhibits PTB binding and the mutated fosB RNA was more efficiently spliced both in vitro and in vivo. This result is in agreement with several studies in which PTB was shown to repress splicing [18], [22], [32], [33], [34]. Because the CU-rich sequence overlaps with the predicted binding site of U2AF65, a factor that recognizes the polypyrimidine stretch at the 3′ end of introns, one possible mechanism of PTB function is a simple competition for the binding site [22]. Our finding that depletion of PTB from the HeLa nuclear extract resulted in binding of U2AF65 to the wild type sequence supports this mechanism. However, in conjunction with competition between splicing factors, other mechanisms may play a role in the regulation of fosB pre-mRNA splicing by PTB. One such example could be the regulation of propagative binding of PTB along a specific segment of the pre-mRNA [22]. Recent work has suggested that repression of splicing of the SM exon within the α-actinin pre-mRNA may be due the cooperative binding of PTB within the 3′ end of the upstream intron out-competing the binding of U2AF65 to the polypyrimidine tract [35]. Examination of the sequence of the fos gene using the biocomputational tool EMBL-EBI Splicing Rainbow ( revealed the presence of three putative PTB binding sites within I4 and exon 5. The alteration of the splice ratios of transcripts containing I4 within HeLa cells co-transfected with ISS/T6 and PTB 1 suggests that under certain conditions additional PTB binding sites within the fos B pre-mRNA may play a role in splicing regulation. The successive binding of PTB may itself be regulatory by interfering with the binding of other splicing factors, and/or functioning to create a scaffold on the pre-mRNA through the molecular interactions between the bound PTB proteins. Interactions between upstream and downstream bound PTB could result in a looping of the RNA, thereby shielding specific sequences from functionally interacting with both splicing enhancing factors and the spliceosome [22]. Results from the ISS/T6 mutation clearly indicate the importance of PTB binding to the 3′ end of I4 for the regulated splicing of fos B pre-mRNA. We are currently examining if interactions between PTB bound at the 3′ end of I4 and additional sites on the fos B pre-mRNA are important for regulated splicing.

While preceding models of PTB function suggest a mechanism of splicing repression by obstruction of splice sites or averting interaction with the spliceosome through looping of the pre-mRNA [22], [33], [34], recent data from the Fas and c-src model systems suggest a more complex mechanism [36], [37]. The proposed mechanism involves specific interference with the bridging between U1 small nuclear ribonucleoprotein (snRNP) and U2AF65 that is responsible for intron and exon definition. This form of interference cannot be ruled out in the fosB model. A unique aspect in the fosB model that makes it different from the one proposed by Sharma and colleagues [37] is that the I4 3′ splice site is a weak splice site that contains a pseudo 5′ splice site with a putative U1 binding site at the I4/E5 border. If U1 snRNP associated factors indeed bind this site it would most likely block the binding of factors required for the recognition of the 3′ splice site. Further studies are needed to determine if PTB simply obstructs the fosB splice site or perhaps prevents cross-talk between components of the spliceosome and whether factors that bind the 5′ splice site are also involved in the regulation of splicing.

Adding further complexity to the regulation of alternative splicing by PTB is its relationship to brain PTB (nPTB). This splicing factor is a paralog of PTB that is enriched in neurons and a few other tissues [27], [38], [39], [40]. Although these two highly homologous proteins can interact with the same cis-elements on RNAs, nPTB is a significantly weaker silencer of splicing than PTB [41]. Interestingly, during neuronal differentiation PTB levels are decreased via the action of a neuron-specific microRNA which results in a concurrent increase in the level of nPTB [42]. Additionally, siRNA induced knockdown of PTB also induces the expression of nPTB [27], [43]. It is possible that we did not observe significant alterations in the splicing of fosB transcripts in cells in which PTB had been knockdown due to this phenomenon (Marinescu and Potashkin, unpublished). The analysis of the intricate dynamics between these proteins indicates that exon populations possess a graded sensitivity to the repressive effects of the individual PTB paralogs [43]. We have determined that nPTB can bind to the 3′ end of I4 (data not shown). Whether this binding is relevant to the splicing of fosB pre-RNA within the brain is currently unknown but is a focus of ongoing analysis.

The other unique aspect of the function of PTB in the splicing of fosB is that it is an example of intron retention, as opposed to its normal role in exon skipping. Alternative splicing is a common mechanism for producing multiple products from a single gene. Intron retention, however, is a relatively rare form of regulated splicing in vertebrates [44], [45], though it is more prominent in viral splicing. Interestingly, a recent study identified 88 examples in which a retained intron produced a truncated protein in humans and in 40% of these cases the premature stop codon was present in the last exon, similar to fosB [44]. In vertebrates, one well-studied example of intron retention that is similar to fosB is bovine growth hormone (bGH) [46]. The regulated intron of bGH also has suboptimal splice sites. The splicing of bGH is regulated by two constitutive splicing factors; SF2/ASF stimulates removal of the final bGH intron and hnRNP A1 inhibits its splicing [47]. Our results showing that PTB, formerly referred to as hnRNP I, regulates fosB splicing are consistent with the idea that suboptimal splice sites are sensitive to fluctuations in regulatory splicing factors. To our knowledge this is the first example of PTB playing a role in intron retention.

Phosphorylation of PTB is Critical for RNA Binding

The key factor important for recognition of the suboptimal fosB I4 splice sites may simply be the amount and/or type of PTB present in the nucleus where regulation is occurring. Our novel finding that only phosphorylated PTB binds to the 3′ intron sequence can be interpreted as evidence that phosphorylation of this splicing factor is important for regulation. Recently, it has been shown that PTB shuttles between the nucleus and cytoplasm, and, that this movement is dependent on the phosphorylation of PTB [26]. Specifically, phosphorylation on Ser16 can sequester PTB in the cytoplasmic compartment. These studies did not rule out the possibility of PTB being phosphorylated on additional sites. Ser16 of PTB is not within the RNA binding domains of PTB. This would suggest that the effects of PTB phosphorylation observed in our studies may be due to phosphorylation by PKA on additional sites that are important for RNA/protein interactions. We are currently performing mutational analysis of the PKA sites within PTB to determine which site(s) are critical for regulation of fosB splicing. Additionally, further studies to characterize the distribution of phosphorylated PTB under conditions in which the splicing of fosB is regulated are being carried out in order to fully understand the role PTB in this process.

Materials and Methods

Cloning and mutagenesis

A minigene construct containing the last 156 nucleotides (nt) of exon 4 (E4), I4 and the first 167 nt of exon 5 (E5) of Mus musculus fosB was created for use as a template for splicing and binding assays (a gift of Dr. Y. Nakabeppu, Kyushu University, Japan). The fosB minigene was amplified by PCR and subcloned into both the pGEM-T Easy plasmid (Promega, Madison, WI), adjacent to the T7 promoter to create pEZ_ISS/WT, and a modified pGL3 plasmid (Promega), adjacent to a SV40 promoter to create ISS/WT for transfection studies.

pEZ ISS/WT was used as a template to generate the mutant pEZ_ ISS/T6. A set of complementary oligonucleotides containing the desired mutations was synthesized (Table 1) and used as primers for site-directed mutagenesis using a Quickchange kit (Stratagene, La Jolla, CA). Nucleotides 128 and 130 within the alternatively spliced intron were changed from C to T (C128T129C130→TTT), in order to convert a putative PTB-binding site into a pyrimidine-rich sequence not recognized by PTB. The mutated fosB minigene was amplified by PCR using 50 ng of pEZ_ISS/WT construct, 125 ng of sense and anti-sense primers, 0.2 mM each of dTTP, dATP, dCTP and dGTP and 2.5 U of PfuTurbo DNA polymerase (Stratagene) in a buffer containing 10 mM KCl, 10 mM (NH4)2SO4, 20 mM Tris-HCl (pH 8.8), 2 mM MgSO4, 0.1% Triton X-100 and 0.1 mg/ml bovine serum albumin (BSA). Eight percent dimethylsulphoxide (DMSO) was added to the reaction to increase the specific binding of the primers. The cycling parameters used were as follows: denature at 95°C for 30 sec, 20–30 cycles at 95°C for 30 sec, 55°C for 1 min, and 68°C for 8 min. Reactions were cooled to 37°C and incubated with Dpn I (10 U/µl) for 1 hr in order to digest the parental template so that only mutated DNA remains. Constructs were sequenced to confirm that the mutation. The pEZ_ISS/T6 sequence was also subcloned into a modified pGL3 plasmid (Promega), adjacent to a SV40 promoter to create ISS/T6 for transfection studies.

Nuclear extract preparation, transcription and in vitro splicing assays

Soluble extracts were prepared from nuclei isolated from 11 liters of HeLa cells grown in spinner cultures using a modification of the Dignam method [48], [49]. Templates for splicing substrates were generated by digestion of pEZ_ISS/WT with Nar I. Labeled RNA was synthesized from linear plasmid in a 50 µl reaction containing 2 µg of DNA, 0.4 mM each of ATP and GTP, 0.1 mM UTP and CTP, 2.5 µl of [32P]-UTP and [32P]-CTP (ICN), 0.5 mM diguanosine triphosphate and 2 µl of 20 U/µl T7 RNA polymerase Plus (Ambion, Austin, TX). Reactions were incubated at 37°C for 1 hr and then digested with DNase I for 15 min at 37°C. Transcripts were purified on 4% denaturing polyacrylamide gels, cut from the gel and eluted on a rotating platform in RNA elution buffer containing 2 M ammonium acetate, 1% SDS and 25 µg/ml yeast tRNA at 37°C overnight. RNA substrate was then extracted with phenol:chloroform and ethanol precipitated. In vitro splicing assays were done as previously described using 11 µl of HeLa extract (2.6 µg/µl) in a total reaction of 25 µl [50]. Spliced products were separated on 4% denaturing polyacrylamide gels.

Templates for intronic transcripts were prepared by PCR using oligonucleotides listed in Table 1. All forward primers contained a T7 RNA polymerase promoter. Each PCR reaction (20 µl) contained 0.88 ng of pEZ_ISS/WT template, 20 pmol of each primer, 0.25 µl Taq polymerase (5U/µl, Promega), 2 µl of 10× Taq buffer (Promega) and 1 µl of dNTP mix containing 10 mM dATP, dCTP, dGTP and dTTP. The parameters were as follows for 35 cycles: denaturation at 94°C for 15 sec, annealing for 15 sec at variable temperatures dependent upon the primers (5′ intron template primers: 53.3°C, middle intron template primers: 73.1°C, and 3′ intron template primers: 67.9°C), and extension: 72°C for 30 sec. PCR reactions were then extracted with phenol:chloroform and ethanol precipitated.

Intronic transcripts were prepared using PCR generated templates. Transcription reactions (50 µl) contained 2 µg of template, 2.5 µl of 200 U/µl T7 RNA polymerase Plus (Ambion), transcription buffer (Ambion), 16 mM MgCl2, 10 mM dithiothreitol (DTT), 4 mM each of ATP, CTP, GTP and UTP and 40 units of RNasin (Promega). Reactions were incubated at 37°C for 1–2 hr and then RQ DNAse (Promega) was added and incubated for an additional 15 min. RNA was phenol:chloroform extracted, ethanol precipitated and resuspended in water. RNA was quantified by measuring absorbance at 260 nm.

Radioactively-labeled intron transcripts were synthesized in 50 µl reactions containing 1 µg of PCR generated template, 0.5 mM each of ATP and GTP, 0.1 mM UTP and CTP, 2.5 µl of [32P]-UTP and [32P]-CTP (ICN) and 2 µl of 200 U/µl T7 RNA polymerase Plus (Ambion). Reactions were incubated at 37°C for 1 hr and then digested with DNase I for 15 min at 37°C. Transcripts were purified on 10% denaturing polyacrylamide gels and then processed as described for the splicing substrates.

Identification of fosB splicing products

Products of splicing reactions using transcripts generated from the fosB minigene constructs were cut out of the gel and eluted overnight in Elution Buffer. RNA was ethanol precipitated and reverse transcribed into cDNA (SuperScript II RT, Stratagene) in a 20 µl reaction containing 50 ng random primers, 5 µl of RNA and 1 µl dNTP mix (10 mM each). The mixture was heated to 65°C for 5 min and 4 µl of 5× first strand buffer, 2 µl of 0.1 M DTT and 1 µl RNaseOUT (40 units/µl) were added to the reaction. SuperScript II RT (1 µl, 200 U/µl, Invitrogen, Carlsbad, CA) was added to the reaction and incubated at 42°C for 50 minutes. The reaction was inactivated by incubation for 15 min at 70°C. PCR reactions (50 µl) contained 5 µl 10× PCR buffer (200 mM Tris-HCl pH 8.4, 500 mM KCl), 1.5 µl 50 mM MgCl2, 10 mM dNTP mix, 1 µl forward primer (10 µM), 1 µl reverse primer (10 µM), 0.4 µl Taq DNA polymerase (5U/µl) and 2 µl cDNA. When intron 4 spliced (IS) and intron 4 retained (IR) RNAs were amplified, a set of E4- and E5-specific primers were used (Table 1). An I4-specific forward primer and an E5-specific reverse primer were used to amplify lariat structures (Table 1). Samples underwent 35 cycles of amplification using the following cycling parameters: 15 sec at 94°C, 15 sec at 60°C or 66°C depending on the primers used, and 30 sec at 68°C. The PCR products were separated on 2% agarose gels.

UV cross-linking assays

UV cross-linking assays were done as previously described [51]. Assays contained 50,000 cpm of [32P]UTP labeled 5′, middle and 3′ substrates in a 10 µl reaction containing 5 µl of HeLa extract (2.6 µg/µl). UV cross-linking reactions were assembled on ice, incubated for 3 min at 30°C and then irradiated in open 1.5 ml centrifuge tubes with 1.2 J, 6.5 cm from a UV light source using a Stratalinker (Stratagene). After exposure to UV light, the reactions were incubated with RNase A (1 mg/ml, Sigma-Aldrich, Saint Louis, MO) for 20 min at 30°C. Reactions were terminated by the addition of protein loading buffer and heating at 95°C for 5 min before loading on 10% SDS polyacrylamide gels. The gels were fixed with 45% methanol and 9% acetic acid before drying and exposing to film.

UV cross-linking immunoprecipitations

Uniformly-labeled [32P]UTP 5′, middle or 3′ RNA substrates were UV cross-linked and RNase A treated as described above. A 10 µl aliquot of a 1:50 dilution of the anti-PTB antibody, Bb7 [52] (a gift of Dr. D.L. Black, UCLA), anti-U2AF65 (Santa Cruz Biotechnology, Santa Cruz, CA) or nonspecific antibody (anti-RIF 2C1, a gift of Dr. K. Beaman, RFUMS) was added to each reaction and incubated at 4°C overnight. The following day 20 µl of Protein A agarose (Roche Diagnostics, Mannheim, Germany) was added to each reaction prior to incubation at room temperature for 1 hr. NET buffer (1 ml) containing 50 mM TrisHCl pH 7.5, 150 mM NaCl, 5 mM EDTA and 0.5% NP40 was added to each sample. Precipitates were collected by centrifugation at 600 × g at 4°C for 30 sec. The samples were washed four times in NET buffer. After the final wash the precipitate was resuspended in loading buffer, boiled for 3 min and then loaded on 10% SDS polyacrylamide gels. The gels were fixed with 45% methanol and 9% acetic acid before drying and exposing to film.

Cell Culture and Transient expression assays

HeLa cells were cultured in DMEM supplemented with 10% fetal bovine serum. His-tagged PTB 1 (human PTB 1, a gift from Dr. J. Patton, Vanderbilt University), was transiently transfected into HeLa cells plated at ~75% confluency in a 100 mm culture dish using the Lipofectamine reagent (Invitrogen) according to the manufacturer's protocol. Twenty four hours after transfection the cells were trypsinized and replated into two 100 mm culture dishes and cell lysates were collected the following day for protein isolation as described below. Slight modifications of the methods described above were also used to transiently transfect pBS (bluescript); ISS/WT; ISS/T6; and PTB 1 constructs into HeLa cells for RNA analysis. Cells were plated into 12 well culture plates (~35% confluency) ~4 hr prior to transfection. Each experimental condition was performed in duplicate. Additionally, each experimental protocol was performed at least three times. Forty-eight hr post-transfection RNA was isolated using the Trizol method, DNase-treated as described above, and cDNA generated. The cDNA was amplified by PCR using a forward primer designed to be complementary to sequence within the pGL3 vector, therefore, only ectopically expressed fosB sequence was amplified. The reverse primer was located in exon 5, thus allowing the amplification of both fosB and ΔfosB cDNA in a PCR reaction with a single set of primers. Control PCR reactions with primers specific for GAPDH were also performed. The amplified products were resolved on 2.5% agarose gels then imaged and quantitated using Kodak 1D Image Analysis Software (Kodak, Rochester, NY).

PTB protein isolation

The Ni-NTA Purification System (Invitrogen) was used for the purification of polyhistidine-containing recombinant proteins. Cells were suspended in 1.5 ml native binding buffer (250 mM NaH2PO4 pH 8.0/2.5 M NaCl) supplemented with a protease inhibitor cocktail (Roche Diagnostics) and a phosphatase inhibitor cocktail (1[ratio]100, Sigma-Aldrich). Cells were lysed by a freeze-thaw cycle and the DNA sheared by passing the resulting cell lysate through an 18-gauge needle followed by centrifuged at 3,000×g for 15 min. Ni-NTA columns were prepared by washing 75 µl of Ni-NTA agarose three times with native binding buffer. Lysate (1.5 ml) was then incubated on the column for 30 min, followed by four washes with native wash buffer (native binding buffer supplemented with 20 mM imidazole, pH 8.0). The supernatant was discarded and protein was eluted with 150 µl native elution buffer (native binding buffer supplemented with 250 mM imidazole, pH 8.0). Extracts were loaded into Slide-A-Lyzer Mini Dialysis Units (10,000 MWCO, Pierce, Rockford, IL) and dialyzed overnight into Buffer D (20 mM HEPES-KOH pH 8.0, 20% glycerol, 100 mM KCl and 0.2 mM EDTA pH 7.9). Purified proteins were examined by Western blotting using PTB or His-tag specific antibodies.

Phosphatase treatment and PKA assay

Uniformly-labeled [32P]UTP and [32P]CTP fosB RNA substrates containing the 3′ end of I4 were UV cross-linked and RNase A treated as described above. Six microliters of purified His-tagged PTB (0.25 µg/µl) was used in the cross-linking assays. For phosphatase treatment, protein was pre-incubated for 15 min with NE Buffer 3 (50 mM Tris-HCl pH 7.9, 100 mM NaCl, 10 mM MgCl2 and 1 mM DTT) followed by a 50 min incubation at 37°C with 3 µl (10 U/µl) of calf intestinal alkaline phosphatase (CIP, New England Biolabs, Ipswitch, MA). For the PKA phosphorylation reaction, protein was incubated with 3 µl of the catalytic subunit of cAMP dependent protein kinase (New England Biolabs, 2,500 U/µl), 200 µM ATP, 1× PKA Reaction Buffer (50 mM Tris-HCl pH 7.5 and 10 mM MgCl2) in a total reaction volume of 30 µl, for 1 hr at 30°C. Some of the His-tagged protein samples were phosphatase and PKA treated. In these instances, the phosphatase step was performed while the protein was still on the nickel beads, followed by wash out of the phosphatase, elution of the His-tagged protein and subsequent PKA treatment.

Western blot analysis

Samples were mixed with an equal volume of 2× SDS sample buffer (125 mM TrisHCl pH 6.8, 20% glycerol, 4% SDS, 0.2% 2-mercaptoethanol (2-ME) and 0.001% bromphenol blue), boiled for 3 min and resolved by electrophoresis in an 8% SDS-polyacrylamide gel. Proteins were transferred to PVDF-Plus transfer membranes (Fisher Scientific, Pittsburgh, PA) for immunoblotting, using a semi-dry transfer apparatus (Owl Scientific, Woburn, MA) according to manufacturer's instructions.

PVDF membranes were then rinsed three times in 0.1% Tween-20 in TBS (TBS-T), blocked with 2% milk for 1 hr at room temperature, incubated with either PTB antibody (1/4,000 dilution; a gift of Dr. D.L. Black, UCLA) overnight at 4°C, washed with TBS-T and incubated for 60 min at room temperature with ECL peroxidase-labelled anti-mouse IgG (1/4,000; Amersham Biosciences). After three final washes in TBS-T, membranes were rinsed in TBS, immersed in chemiluminescence detection reagent (ECL Plus, Amersham Biosciences) and exposed to HyperFilm ECL film (Amersham Biosciences). Antibodies were stripped from the membrane by incubating in 62.5 mM TrisHCl (pH 6.8), 2% SDS, 100 mM 2-ME at 50°C for 30 min. Blots were then probed with an α-polyhistidine antibody (1/3,000 dilution; Clone His 1, Sigma-Aldrich). Images were captured using Kodak 1D Image Analysis Software.

PTB depletion

Transcripts which have been shown to effectively deplete PTB from HeLa nuclear extracts [53] were generated from a plasmid containing the CUCUU-octamer sequence (a gift of Dr. C.W. Smith, University of Cambridge). RNA transcription was carried out in the presence of 100 µM biotin-14-CTP as previously described [53]. The biotinylated RNA was then bound to streptavidin magnetic beads (Invitrogen; 100 pmol of RNA/50 µl of beads) in 2× BW buffer (10 mM TrisHCl pH 7.5, 1 mM EDTA, 2 M NaCl). One hundred microliters of HeLa nuclear extract (2.6 µg/µl) was preincubated with 0.5 µl of 100 mM DTT and 34 U of RNasin for 15 min at room temperature, followed by incubation with the RNA-streptavidin beads for 30 min, using 1,440 fmol of RNA/µl of extract. The beads were removed from the extract using a magnet as described by the manufacturer.


We thank Drs. D.L. Black for anti-PTB monoclonal antibody Bb7, and PTB plasmid, K. Beaman for the anti-RIF 2C1 control antibody, J. Patton for His-tagged PTB1 plasmid, C.W. Smith for the plasmid containing the CUCUU-octamer sequence, Y. Nakabeppu for fosB minigene plasmid, and K.E. Neet for scientific discussion and advice. The technical assistance of Vladimir Strunin is gratefully acknowledged.


Competing Interests: The authors have declared that no competing interests exist.

Funding: This work was supported by National Institutes of Health grants DA-13703 and DA-15367 to JP.


1. Nestler EJ, Kelz MB, Chen J. DeltaFosB: a molecular mediator of long-term neural and behavioral plasticity. Brain Res. 1999;835:10–17. [PubMed]
2. Perez-Otano I, Mandelzys A, Morgan JI. MPTP-Parkinsonism is accompanied by persistent expression of a delta-FosB-like protein in dopaminergic pathways. Brain Res Mol Brain Res. 1998;53:41–52. [PubMed]
3. Perrotti LI, Hadeishi Y, Ulery PG, Barrot M, Monteggia L, et al. Induction of DeltaFosB in reward-related brain structures after chronic stress. J Neurosci. 2004;24:10594–10602. [PubMed]
4. Hiroi N, Marek GJ, Brown JR, Ye H, Saudou F, et al. Essential role of the fosB gene in molecular, cellular, and behavioral actions of chronic electroconvulsive seizures. J Neurosci. 1998;18:6952–6962. [PubMed]
5. Miyata S, Tsujioka H, Itoh M, Matsunaga W, Kuramoto H, et al. Time course of Fos and Fras expression in the hypothalamic supraoptic neurons during chronic osmotic stimulation. Brain Res Mol Brain Res. 2001;90:39–47. [PubMed]
6. Hope BT, Nye HE, Kelz MB, Self DW, Iadarola MJ, et al. Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron. 1994;13:1235–1244. [PubMed]
7. Chen J, Kelz MB, Hope BT, Nakabeppu Y, Nestler EJ. Chronic Fos-related antigens: stable variants of deltaFosB induced in brain by chronic treatments. J Neurosci. 1997;17:4933–4941. [PubMed]
8. Alibhai IN, Green TA, Potashkin JA, Nestler EJ. Regulation of fosB and DeltafosB mRNA expression: in vivo and in vitro studies. Brain Res. 2007;1143:22–33. [PMC free article] [PubMed]
9. Chen J, Nye HE, Kelz MB, Hiroi N, Nakabeppu Y, et al. Regulation of delta FosB and FosB-like proteins by electroconvulsive seizure and cocaine treatments. Mol Pharmacol. 1995;48:880–889. [PubMed]
10. Acquaviva C, Brockly F, Ferrara P, Bossis G, Salvat C, et al. Identification of a C-terminal tripeptide motif involved in the control of rapid proteasomal degradation of c-Fos proto-oncoprotein during the G(0)-to-S phase transition. Oncogene. 2001;20:7563–7572. [PubMed]
11. Ulery PG, Rudenko G, Nestler EJ. Regulation of DeltaFosB stability by phosphorylation. J Neurosci. 2006;26:5131–5142. [PubMed]
12. Graveley BR. Alternative splicing: increasing diversity in the proteomic world. Trends Genet. 2001;17:100–107. [PubMed]
13. Modrek B, Resch A, Grasso C, Lee C. Genome-wide detection of alternative splicing in expressed sequences of human genes. Nucleic Acids Res. 2001;29:2850–2859. [PMC free article] [PubMed]
14. Smith CW, Valcarcel J. Alternative pre-mRNA splicing: the logic of combinatorial control. Trends Biochem Sci. 2000;25:381–388. [PubMed]
15. Faustino NA, Cooper TA. Pre-mRNA splicing and human disease. Genes Dev. 2003;17:419–437. [PubMed]
16. Grabowski PJ, Black DL. Alternative RNA splicing in the nervous system. Prog Neurobiol. 2001;65:289–308. [PubMed]
17. Dredge BK, Polydorides AD, Darnell RB. The splice of life: alternative splicing and neurological disease. Nat Rev Neurosci. 2001;2:43–50. [PubMed]
18. Ladd AN, Cooper TA. Finding signals that regulate alternative splicing in the post-genomic era. Genome Biol. 2002;3:reviews0008. [PMC free article] [PubMed]
19. Goren A, Ram O, Amit M, Keren H, Lev-Maor G, et al. Comparative analysis identifies exonic splicing regulatory sequences–The complex definition of enhancers and silencers. Mol Cell. 2006;22:769–781. [PubMed]
20. Black DL. Activation of c-src neuron-specific splicing by an unusual RNA element in vivo and in vitro. Cell. 1992;69:795–807. [PubMed]
21. Zhang L, Ashiya M, Sherman TG, Grabowski PJ. Essential nucleotides direct neuron-specific splicing of gamma 2 pre-mRNA. Rna. 1996;2:682–698. [PubMed]
22. Wagner EJ, Garcia-Blanco MA. Polypyrimidine tract binding protein antagonizes exon definition. Mol Cell Biol. 2001;21:3281–3288. [PMC free article] [PubMed]
23. Lou H, Helfman DM, Gagel RF, Berget SM. Polypyrimidine tract-binding protein positively regulates inclusion of an alternative 3′-terminal exon. Mol Cell Biol. 1999;19:78–85. [PMC free article] [PubMed]
24. Paradis C, Cloutier P, Shkreta L, Toutant J, Klarskov K, et al. hnRNP I/PTB can antagonize the splicing repressor activity of SRp30c. Rna. 2007
25. Mumberg D, Lucibello FC, Schuermann M, Muller R. Alternative splicing of fosB transcripts results in differentially expressed mRNAs encoding functionally antagonistic proteins. Genes Dev. 1991;5:1212–1223. [PubMed]
26. Xie J, Lee JA, Kress TL, Mowry KL, Black DL. Protein kinase A phosphorylation modulates transport of the polypyrimidine tract-binding protein. Proc Natl Acad Sci U S A. 2003;100:8776–8781. [PubMed]
27. Boutz PL, Stoilov P, Li Q, Lin CH, Chawla G, et al. A post-transcriptional regulatory switch in polypyrimidine tract-binding proteins reprograms alternative splicing in developing neurons. Genes Dev. 2007;21:1636–1652. [PubMed]
28. Herdegen T, Leah JD. Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins. Brain Res Brain Res Rev. 1998;28:370–490. [PubMed]
29. Ulery PG, Nestler EJ. Regulation of DeltaFosB transcriptional activity by Ser27 phosphorylation. Eur J Neurosci. 2007;25:224–230. [PubMed]
30. Nestler EJ. Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci. 2001;2:119–128. [PubMed]
31. Nakabeppu Y, Nathans D. A naturally occurring truncated form of FosB that inhibits Fos/Jun transcriptional activity. Cell. 1991;64:751–759. [PubMed]
32. Valcarcel J, Gebauer F. Post-transcriptional regulation: the dawn of PTB. Curr Biol. 1997;7:R705–708. [PubMed]
33. Singh R, Valcarcel J, Green MR. Distinct binding specificities and functions of higher eukaryotic polypyrimidine tract-binding proteins. Science. 1995;268:1173–1176. [PubMed]
34. Lin CH, Patton JG. Regulation of alternative 3′ splice site selection by constitutive splicing factors. Rna. 1995;1:234–245. [PubMed]
35. Matlin AJ, Southby J, Gooding C, Smith CW. Repression of {alpha}-actinin SM exon splicing by assisted binding of PTB to the polypyrimidine tract. Rna. 2007
36. Izquierdo JM, Majos N, Bonnal S, Martinez C, Castelo R, et al. Regulation of Fas alternative splicing by antagonistic effects of TIA-1 and PTB on exon definition. Mol Cell. 2005;19:475–484. [PubMed]
37. Sharma S, Falick AM, Black DL. Polypyrimidine tract binding protein blocks the 5′ splice site-dependent assembly of U2AF and the prespliceosomal E complex. Mol Cell. 2005;19:485–496. [PMC free article] [PubMed]
38. Ashiya M, Grabowski PJ. A neuron-specific splicing switch mediated by an array of pre-mRNA repressor sites: evidence of a regulatory role for the polypyrimidine tract binding protein and a brain-specific PTB counterpart. Rna. 1997;3:996–1015. [PubMed]
39. Kikuchi T, Ichikawa M, Arai J, Tateiwa H, Fu L, et al. Molecular cloning and characterization of a new neuron-specific homologue of rat polypyrimidine tract binding protein. J Biochem (Tokyo) 2000;128:811–821. [PubMed]
40. Polydorides AD, Okano HJ, Yang YY, Stefani G, Darnell RB. A brain-enriched polypyrimidine tract-binding protein antagonizes the ability of Nova to regulate neuron-specific alternative splicing. Proc Natl Acad Sci U S A. 2000;97:6350–6355. [PubMed]
41. Markovtsov V, Nikolic JM, Goldman JA, Turck CW, Chou MY, et al. Cooperative assembly of an hnRNP complex induced by a tissue-specific homolog of polypyrimidine tract binding protein. Mol Cell Biol. 2000;20:7463–7479. [PMC free article] [PubMed]
42. Makeyev EV, Zhang J, Carrasco MA, Maniatis T. The MicroRNA miR-124 Promotes Neuronal Differentiation by Triggering Brain-Specific Alternative Pre-mRNA Splicing. Mol Cell. 2007;27:435–448. [PubMed]
43. Spellman R, Llorian M, Smith CW. Crossregulation and Functional Redundancy between the Splicing Regulator PTB and Its Paralogs nPTB and ROD1. Mol Cell. 2007;27:420–434. [PMC free article] [PubMed]
44. Galante PA, Sakabe NJ, Kirschbaum-Slager N, de Souza SJ. Detection and evaluation of intron retention events in the human transcriptome. Rna. 2004;10:757–765. [PubMed]
45. Zavolan M, van Nimwegen E. The types and prevalence of alternative splice forms. Curr Opin Struct Biol. 2006;16:362–367. [PubMed]
46. Hampson RK, Rottman FM. Alternative processing of bovine growth hormone mRNA: nonsplicing of the final intron predicts a high molecular weight variant of bovine growth hormone. Proc Natl Acad Sci U S A. 1987;84:2673–2677. [PubMed]
47. Sun Q, Mayeda A, Hampson RK, Krainer AR, Rottman FM. General splicing factor SF2/ASF promotes alternative splicing by binding to an exonic splicing enhancer. Genes Dev. 1993;7:2598–2608. [PubMed]
48. Dignam JD, Martin PL, Shastry BS, Roeder RG. Eukaryotic gene transcription with purified components. Methods Enzymol. 1983;101:582–598. [PubMed]
49. Mayeda A, Krainer AR. Preparation of HeLa cell nuclear and cytosolic S100 extracts for in vitro splicing. Methods Mol Biol. 1999;118:309–314. [PubMed]
50. Mayeda A, Krainer AR. Mammalian in vitro splicing assays. Methods Mol Biol. 1999;118:315–321. [PubMed]
51. Zhang L, Liu W, Grabowski PJ. Coordinate repression of a trio of neuron-specific splicing events by the splicing regulator PTB. Rna. 1999;5:117–130. [PubMed]
52. Chou MY, Underwood JG, Nikolic J, Luu MH, Black DL. Multisite RNA binding and release of polypyrimidine tract binding protein during the regulation of c-src neural-specific splicing. Mol Cell. 2000;5:949–957. [PubMed]
53. Southby J, Gooding C, Smith CW. Polypyrimidine tract binding protein functions as a repressor to regulate alternative splicing of alpha-actinin mutally exclusive exons. Mol Cell Biol. 1999;19:2699–2711. [PMC free article] [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science